LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (NASDAQ: STML) investors concerning the Company and its officers’ possible violations of federal securities laws.
Stemline is a clinical stage biopharmaceutical company that focuses on the discovery, acquisition, development and commercialization of proprietary oncology therapeutics in the United States.
On or around January 19, 2017 Stemline announced a proposed secondary offering of 4.5 million shares at $10 per share. Then on February 2, 2017, Bloomberg announced a patient death in a clinical trial for Stemline’s cancer drug SL-401, the third death attributed in part to SL-401.
On this news, the Company's stock fell $4.15 per share, or 42%, to close on February 2, 2017 at $5.60 a share.
If you purchased Stemline securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.